Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers?

The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
Karina HansenMondher Toumi

Abstract

Pharmacoeconomic evaluations are important elements in the decision making process, and decision tree analyses are statistical models that analyse both clinical and economic consequences of medical actions. Using one theoretic model, key confounding variables were identified that constituted a standardised framework for economic evaluation of schizophrenia management. The extent to which they were included in several previously published schizophrenia models was appraised. Five different models were developed, and a systematic review of schizophrenia modelling studies was conducted. Results indicate that atypical antipsychotics may be more or less cost-effective depending upon whether key confounding variables were taken into account, but vigilance is warranted when assessing data because serious discrepancies can occur between different methods of analysis. A need for standardised schizophrenia pharmacoeconomic models exists. Additionally, social rehabilitation should be considered because this may also influence outcomes. Standardising modelling techniques will facilitate adherence to guidelines issued by decision makers.

References

Jan 1, 1983·Medical Decision Making : an International Journal of the Society for Medical Decision Making·J R Beck, S G Pauker
Oct 1, 1993·Medical Decision Making : an International Journal of the Society for Medical Decision Making·F A Sonnenberg, J R Beck
Jan 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·L M Davies, M F Drummond
Jul 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·H J Salize, W Rössler
Jan 28, 1998·Clinical Therapeutics·C Langley-Hawthorne
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Nov 26, 1998·The British Journal of Psychiatry : the Journal of Mental Science·P V TranC M Beasley
May 7, 1997·PharmacoEconomics·F RouillonP Auquier
Oct 28, 1999·PharmacoEconomics·R H Foster, K L Goa
Feb 2, 2000·Psychiatric Services : a Journal of the American Psychiatric Association·M OlfsonP J Weiden
Feb 17, 2000·The Annals of Pharmacotherapy·P S Masand, S L Berry
Sep 8, 2000·PharmacoEconomics·C Evans, B Crawford
Apr 12, 2003·The Lancet Oncology·Peter LittlejohnsUNKNOWN UK National Institute for Clinical Excellence
May 29, 2003·Current Drug Targets. CNS and Neurological Disorders·Robert R Conley, Deanna L Kelly
Jun 5, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Andy DugganRobert Kerwin
Aug 2, 2003·Schizophrenia Research·Rahul GangulyBradley C Martin
Feb 6, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Hans RittmannsbergerJohannes Wancata
Feb 9, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·P LecomteU Persson
Jan 1, 1998·International Journal of Psychiatry in Clinical Practice·C Gillberg, M Rårstam
Jan 1, 1998·International Journal of Psychiatry in Clinical Practice·B D ByromA T Kilpatrick

❮ Previous
Next ❯

Citations

Jan 20, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Bertalan NémethBalázs Nagy
Dec 1, 2007·Acta Neuropsychiatrica·Mario AmoreRobin McCreadie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2021 Meta ULC. All rights reserved